| Literature DB >> 24111611 |
Omar Al Ustwani1, Razelle Kurzrock, Meir Wetzler.
Abstract
We initially described the WHIM syndrome based on the combination of Warts, Hypogammaglobulinaemia, Infections and Myelokathexis (neutrophil retention in the bone marrow). Translational research led to the discovery that this rare immunodeficiency disease is caused by a heterozygous mutation in the CXCR4 gene. Recently, Plerixafor has been suggested as a treatment for WHIM syndrome due to its efficacy as a CXCR4 antagonist, closing the translational research loop. In this review, we will focus on the clinical manifestations, pathophysiology, diagnosis and possible therapies for this rare entity.Entities:
Keywords: CXCR4; WHIM; myelokathexis; neutropenia; plerixafor
Mesh:
Substances:
Year: 2013 PMID: 24111611 PMCID: PMC3961560 DOI: 10.1111/bjh.12574
Source DB: PubMed Journal: Br J Haematol ISSN: 0007-1048 Impact factor: 6.998